1 Searfoss, G. H., T. P. Ryan, and R. A. Jolly. The role of transcriptome analysis in pre-clinical toxicology. Curr. Mol. Med. 2005, 5, 53-64.

2 Terry, C., A. Dhawan, R. R. Mitry, S. C. Lehec, and R. D. Hughes. Preincubation of rat and human hepatocytes with cytoprotectants prior to cryopreservation can improve viability and function upon thawing. Liver Transpl. 2006, 12, 165-177.

3 Kafert-Kasting, S., K. Alexandrova, M. Barthold, B. Laube, G. Friedrich, L. Arseniev, and J. G. Hengstler. Enzyme induction in cryopreserved human hepatocyte cultures. Toxicology 2006, 220, 117-1125.

4 Boess, F., M. Kamber, S. Romer, R. Gasser, D. Muller, S. Albertini, and L. Suter. Gene expression in two hepatic cell lines, cultured primary hepatocytes, and liver slices compared to the in vivo liver gene expression in rats: possible implications for toxicogenomics use of in vitro systems. Toxicol. Sci. 2003, 73, 386-402.

5 Jessen, B. A., J. S. Mullins, A. De Peyster, and G. J. Stevens. Assessment of hepatocytes and liver slices as in vitro test systems to predict in vivo gene expression. Toxicol. Sci. 2003, 75, 208-222.

6 MacGregor, J. T., J. M. Collins, Y. Sugiyama, C. A. Tyson, J. Dean, L. Smith, M. Andersen, R. D. Curren, J. B. Houston, F. F. Kadlubar, G. L. Kedderis, K. Krishnan, A. P. Li, R. E. Parchment, K. Thummel, J. E. Tomaszewski,

R. Ulrich, A. E. Vickers, and S. A. Wrighton. In vitro human tissue models in risk assessment: report of a consensus-building workshop. Toxicol. Sci. 2001, 59, 17-36.

7 Klaunig, J. E., M. A. Babich, K. P. Baetcke, J. C. Cook, J. C. Corton, R. M. David, J. G. DeLuca, D. Y. Lai, R. H. McKee, J. M. Peters,

R. A. Roberts, and P. A. Fenner-Crisp. PPARalpha agonist-induced rodent tumors: modes of action and human relevance. Crit. Rev. Toxicol. 2003, 33, 655-780.

8 Brandon, E. F., C. D. Raap, I. Meijerman, J. H. Beijnen, and

J. H. Schellens. An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons. Toxicol. Appl. Pharmacol. 2003, 189, 233-246.

9 Meunier, V., M. Bourrie, Y. Berger, and G. Fabre. The human intestinal epithelial cell line Caco-2; pharmacological and pharmacokinetic applications. Cell Biol. Toxicol. 1995, 11, 187-194.

10 Bock, K. W., and C. Kohle. UDP-glucuronosyltransferase 1A6: structural, functional, and regulatory aspects. Methods Enzymol. 2005, 400, 57-75.

11 Berger, V., A. F. Gabriel, T. Sergent, A. Trouet, Y. Larondelle, and

Y. J. Schneider. Interaction of ochratoxin A with human intestinal Caco-2 cells: possible implication of a multidrug resistance-associated protein (MRP2). Toxicol. Lett. 2003, 140-141, 465-476.

12 Pleasure, S. J., C. Page, and V. M. Lee. Pure, postmitotic, polarized human neurons derived from NTera 2 cells provide a system for expressing exogenous proteins in terminally differentiated neurons. J. Neurosci. 1992, 12, 1802-1815.

13 Megiorni, F., B. Mora, P. Indovina, and M. C. Mazzilli. Expression of neuronal markers during NTera2/cloneD1 differentiation by cell aggregation method. Neurosci. Lett. 2005, 373, 105-109.

14 Gortz, P., W. Fleischer, C. Rosenbaum, F. Otto, and M. Siebler. Neuronal network properties of human teratocarcinoma cell line-derived neurons. Brain Res. 2004, 1018, 18-25.

15 O'Connor, J. E., A. Martinez, J. V. Castell, and M. J. Gomez-Lechon. Multiparametric characterization by flow cytometry of flow-sorted subpopulations of a human hepatoma cell line useful for drug research. Cytometry A 2005, 63, 48-58.

16 Guan, K., K. Nayernia, L. S. Maier, S. Wagner, R. Dressel, J. H. Lee, J. Nolte, F. Wolf, M. Li, W. Engel, and G. Hasenfuss. Pluripotency of spermatogonial stem cells from adult mouse testis. Nature 2006, 440, 1199-1203.

17 Hahn, W. C., and R. A. Weinberg. Modelling the molecular circuitry of cancer. Nat. Rev. Cancer 2002, 2, 331-341.

18 Nasir, L., P. Devlin, T. McKevitt, G. Rutteman, and D. J. Argyle. Telomere lengths and telomerase activity in dog tissues: a potential model system to study human telomere and telomerase biology. Neoplasia 2001, 3, 351-359.

19 Cerezo, A., H. Kalthoff, M. Schuermann, B. Schafer, and P. Boukamp. Dual regulation of telomerase activity through c-Myc-dependent inhibition and alternative splicing of hTERT. J. Cell Sci. 2002, 115, 1305-1312.

20 Bodnar, A. G., M. Ouellette, M. Frolkis, S. E. Holt, C. P. Chiu, G. B. Morin,

C. B. Harley, J. W. Shay, S. Lichtsteiner, and W. E. Wright. Extension of lifespan by introduction of telomerase into normal human cells. Science 1998, 279, 349-352.

21 Dickson, M. A., W. C. Hahn, Y. Ino, V. Ronfard, J. Y. Wu, R. A. Weinberg,

D. N. Louis, F. P. Li, and J. G. Rheinwald. Human keratinocytes that express hTERT and also bypass a p16(INK4a)-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics. Mol. Cell. Biol. 2000, 20, 1436-1447.

22 O'Hare, M. J., J. Bond, C. Clarke, Y. Takeuchi, A. J. Atherton, C. Berry, J. Moody, A. R. Silver, D. C. Davies, A. E. Alsop, A. M. Neville, and

P. S. Jat. Conditional immortalization of freshly isolated human mammary fibroblasts and endothelial cells. Proc. Natl. Acad. Sci. UJSA 2001, 98, 646-651.

23 Yang, J., E. Chang, A. M. Cherry, C. D. Bangs, Y. Oei, A. Bodnar,

A. Bronstein, C. P. Chiu, and G. S. Herron. Human endothelial cell life extension by telomerase expression. J. Biol. Chem. 1999, 274, 26141-26148.

24 Flores, I., R. Benetti, and M. A. Blasco. Telomerase regulation and stem cell behaviour. Curr. Opin. Cell Biol. 2006, 18, 254-260.

25 Parsch, D., J. Fellenberg, T. H. Brummendorf, A. M. Eschlbeck, and W. Richter. Telomere length and telomerase activity during expansion and differentiation of human mesenchymal stem cells and chondrocytes. J. Mol. Med. 2004, 82, 49-55.

26 Villa, A., B. Navarro-Galve, C. Bueno, S. Franco, M. A. Blasco, and

A. Martinez-Serrano. Long-term molecular and cellular stability of human neural stem cell lines. Exp. Cell Res. 2004, 294, 559-570.

27 Mulloy, J. C., J. Cammenga, F. J. Berguido, K. Wu, P. Zhou, R. L. Comenzo, S. Jhanwar, M. A. Moore, and S. D. Nimer. Maintaining the self-renewal and differentiation potential of human CD34+ hematopoietic cells using a single genetic element. Blood 2003, 102, 4369-4376.

28 Stewart, S. A., W. C. Hahn, B. F. O'Connor, E. N. Banner, A. S. Lundberg, P. Modha, H. Mizuno, M. W. Brooks, M. Fleming, D. B. Zimonjic,

N. C. Popescu, and R. A. Weinberg. Telomerase contributes to tumori-genesis by a telomere length-independent mechanism. Proc. Natl. Acad. Sci. UJSA 2002, 99, 12606-12611.

29 Kumazaki, T., K. Hiyama, T. Takahashi, H. Omatsu, K. Tanimoto,

T. Noguchi, E. Hiyama, Y. Mitsui, and M. Nishiyama. Differential gene expressions during immortalization of normal human fibroblasts and endothelial cells transfected with human telomerase reverse transcriptase gene. Int. J. Oncol. 2004, 24, 1435-1442.

30 Gorbunova, V., A. Seluanov, and O. M. Pereira-Smith. Evidence that high telomerase activity may induce a senescent-like growth arrest in human fibroblasts. J. Biol. Chem. 2003, 278, 7692-7698.

31 Romanov, S. R., B. K. Kozakiewicz, C. R. Holst, M. R. Stampfer,

L. M. Haupt, and T. D. Tlsty. Normal human mammary epithelial cells spontaneously escape senescence and acquire genomic changes. Nature 2001, 409, 633-637.

32 Hahn, W. C., S. K. Dessain, M. W. Brooks, J. E. King, B. Elenbaas, D. M. Sabatini, J. A. DeCaprio, and R. A. Weinberg. Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol. Cell. Biol. 2002, 22, 2111-2123.

33 Ahuja, D., M. T. Saenz-Robles, and J. M. Pipas. SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation. Oncogene 2005, 24, 7729-7745.

34 Shaw, G., S. Morse, M. Ararat, and F. L. Graham. Preferential transformation of human neuronal cells by human adenoviruses and the origin of HEK 293 cells. FASEB J. 2002, 16, 869-871.

35 Giampietri, C., M. Levrero, A. Felici, A. D'Alessio, M. C. Capogrossi, and C. Gaetano. E1A stimulates FGF-2 release promoting differentiation of primary endothelial cells. Cell Death Differ. 2000, 7, 292-301.

36 Batsche, E., M. Lipp, and C. Cremisi. Transcriptional repression and activation in the same cell type of the human c-MYC promoter by the retinoblastoma gene protein: antagonisation of both effects by SV40 T antigen. Oncogene 1994, 9, 2235-2243.

37 Freed, W. J., P. Zhang, J. F. Sanchez, O. Dillon-Carter, M. Coggiano,

S. L. Errico, B. D. Lewis, and M. E. Truckenmiller. Truncated N-terminal mutants of SV40 large T antigen as minimal immortalizing agents for CNS cells. Exp. Neurol. 2005, 191 (Suppl 1), S45-S59.

38 Wynford-Thomas, D., J. A. Bond, F. S. Wyllie, J. S. Burns, E. D. Williams, T. Jones, D. Sheer, and N. R. Lemoine. Conditional immortalization of human thyroid epithelial cells: a tool for analysis of oncogene action. Mol. Cell. Biol. 1990, 10, 5365-5377.

39 Bodine, P. V., S. K. Vernon, and B. S. Komm. Establishment and hormonal regulation of a conditionally transformed preosteocytic cell line from adult human bone. Endocrinology 1996, 137, 4592-4604.

40 Satchell, S. C., C. H. Tasman, A. Singh, L. Ni, J. Geelen, C. J. von Ruhland, J. O'Hare, M. A. Saleem, L. P. van den Heuvel, and P. W. Mathieson. Conditionally immortalized human glomerular endothelial cells expressing fenestrations in response to VEGF. Kidney Int. 2006, 69, 1633-1640.

41 Kim, B. H., S. R. Sung, E. H. Choi, Y. I. Kim, K. J. Kim, S. H. Dong, H. J. Kim, Y. W. Chang, J. I. Lee, and R. Chang. Dedifferentiation of conditionally immortalized hepatocytes with long-term in vitro passage. Exp. Mol. Med. 2000, 32, 29-37.

42 May, T., H. Hauser, and D. Wirth. Transcriptional control of SV40 T-antigen expression allows a complete reversion of immortalization. Nucleic Acids Res 2004, 32, 5529-5538.

43 Paillard, F. Reversible cell immortalization with the Cre-lox system. Hum. Gene Ther. 1999, 10, 1597-1598.

44 Weber, A. Immortalization of hepatic progenitor cells. Pathol. Biol. (Paris) 2004, 52, 93-96.

45 Noguchi, H., N. Kobayashi, K. A. Westerman, M. Sakaguchi, T. Okitsu, T. Totsugawa, T. Watanabe, T. Matsumura, T. Fujiwara, T. Ueda,

M. Miyazaki, N. Tanaka, and P. Leboulch. Controlled expansion of human endothelial cell populations by Cre-loxP-based reversible immortalization. Hum. Gene Ther. 2002, 13, 321-334.

46 Lavia, P., A. M. Mileo, A. Giordano, and M. G. Paggi. Emerging roles of DNA tumor viruses in cell proliferation: new insights into genomic instability. Oncogene 2003, 22, 6508-6516.

47 Ryan, M. J., G. Johnson, J. Kirk, S. M. Fuerstenberg, R. A. Zager, and

B. Torok-Storb. HK-2: an immortalized proximal tubule epithelial cell line from normal adult human kidney. Kidney Int. 1994, 45, 48-57.

48 Reetz, M. T. An overview of high-throughput screening systems for enantio-selective enzymatic transformations. Methods Mol. Biol. 2003, 230, 259-282.

49 Kostenis, E. Potentiation of GPCR-signaling via membrane targeting of G protein alpha subunits. J. Recept. Signal Transduct. Res. 2002, 22, 267-281.

50 Ames, R., P. Nuthulaganti, J. Fornwald, U. Shabon, H. van-der-Keyl, and N. Elshourbagy. Heterologous expression of G protein-coupled receptors in U-2 OS osteosarcoma cells. Receptors Channels 2004, 10, 117-124.

51 Hodges, B. L., K. M. Taylor, M. F. Joseph, S. A. Bourgeois, and

R. K. Scheule. Long-term transgene expression from plasmid DNA gene therapy vectors is negatively affected by CpG dinucleotides. Mol. Ther. 2004, 10, 269-278.

52 Cervoni, N., and M. Szyf. Demethylase activity is directed by histone acetylation. J. Biol. Chem. 2001, 276, 40778-40787.

53 Mutskov, V. J., C. M. Farrell, P. A. Wade, A. P. Wolffe, and G. Felsenfeld. The barrier function of an insulator couples high histone acetylation levels with specific protection of promoter DNA from methylation. Genes Dev. 2002, 16, 1540-1554.

54 Zahn-Zabal, M., M. Kobr, P. A. Girod, M. Imhof, P. Chatellard,

M. de Jesus, F. Wurm, and N. Mermod. Development of stable cell lines for production or regulated expression using matrix attachment regions. J. Biotechnol. 2001, 87, 29-42.

55 Antoniou, M., L. Harland, T. Mustoe, S. Williams, J. Holdstock, E. Yague, T. Mulcahy, M. Griffiths, S. Edwards, P. A. Ioannou, A. Mountain, and

R. Crombie. Transgenes encompassing dual-promoter CpG islands from the human TBP and HNRPA2B1 loci are resistant to heterochromatin-mediated silencing. Genomics 2003, 82, 269-279.

56 Wakabayashi-Ito, N., and S. Nagata. Characterization of the regulatory elements in the promoter of the human elongation factor-1 alpha gene. J. Biol. Chem. 1994, 269, 29831-29837.

57 Running Deer, J., and D. S. Allison. High-level expression of proteins in mammalian cells using transcription regulatory sequences from the Chinese hamster EF-1alpha gene. Biotechnol. Prog. 2004, 20, 880-889.

58 Cai, H. N., Z. Zhang, J. R. Adams, and P. Shen. Genomic context modulates insulator activity through promoter competition. Development 2001, 128, 4339-4347.

59 Wirth, D., and H. Hauser. Flp-mediated integration of expression cassettes into FRT-tagged chromosomal loci in mammalian cells. Methods Mol. Biol. 2004, 267, 467-476.

60 Schlake, T., and J. Bode. Use of mutated FLP recognition target (FRT) sites for the exchange of expression cassettes at defined chromosomal loci. Biochemistry 1994, 33, 12746-12751.

61 Mitsuya, H., K. J. Weinhold, P. A. Furman, M. H. St Clair, S. N. Lehrman, R. C. Gallo, D. Bolognesi, D. W. Barry, and S. Broder. 3'-Azido-3'-deoxy-thymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc. Natl. Acad. Sci. USA 1985, 82, 7096-7100.

62 Lin, T. S., and W. H. Prusoff. Synthesis and biological activity of several amino analogues of thymidine. J. Med. Chem. 1978, 21, 109-112.

63 Felber, B. K., and G. N. Pavlakis. A quantitative bioassay for HIV-1 based on trans-activation. Science 1988, 239, 184-187.

64 Bonnerot, C., N. Savatier, and J. F. Nicolas. [Toward an unpublished method of detecting human retroviruses: activation of HIV-1 LacZ recombinant provirus by the tat gene product]. C. R. Acad. Sci. III 1988, 307, 311-316.

65 Chandra, A., I. Demirhan, S. K. Arya, and P. Chandra. D-penicillamine inhibits transactivation of human immunodeficiency virus type-1 (HIV-1) LTR by transactivator protein. FEBS Lett. 1988, 236, 282-286.

66 Doranz, B. J., K. Grovit-Ferbas, M. P. Sharron, S. H. Mao, M. B. Goetz, E. S. Daar, R. W. Doms, and W. A. O'Brien. A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J. Exp. Med. 1997, 186, 1395-1400.

67 O'Brien, W. A., M. Sumner-Smith, S. H. Mao, S. Sadeghi, J. Q. Zhao, and I. S. Chen. Anti-human immunodeficiency virus type 1 activity of an oligocationic compound mediated via gp120 V3 interactions. J. Virol. 1996, 70, 2825-2831.

68 Hsu, M. C., A. D. Schutt, M. Holly, L. W. Slice, M. I. Sherman, D. D. Richman, M. J. Potash, and D. J. Volsky. Inhibition of HIV replication in acute and chronic infections in vitro by a Tat antagonist. Science 1991, 254, 1799-1802.

69 Haubrich, R. H., C. Flexner, M. M. Lederman, M. Hirsch, C. P. Pettinelli, R. Ginsberg, P. Lietman, F. M. Hamzeh, S. A. Spector, and D. D. Richman. A randomized trial of the activity and safety of Ro 24-7429 (Tat antagonist) versus nucleoside for human immunodeficiency virus infection. The AIDS Clinical Trials Group 213 Team. J. Infect. Dis. 1995, 172, 1246-1252.

70 Cupelli, L. A., and M. C. Hsu. The human immunodeficiency virus type 1 Tat antagonist, Ro 5-3335, predominantly inhibits transcription initiation from the viral promoter. J. Virol. 1995, 69, 2640-2643.

71 Richman, D. D., R. S. Kornbluth, and D. A. Carson. Failure of dideoxy-nucleosides to inhibit human immunodeficiency virus replication in cultured human macrophages. J. Exp. Med. 1987, 166, 1144-1149.

72 Ochsenbauer-Jambor, C., J. Jones, M. Heil, K. P. Zammit, and O. Kutsch. T-cell line for HIV drug screening using EGFP as a quantitative marker of HIV-1 replication. Biotechniques 2006, 40, 91-100.

73 Miyake, H., Y. Iizawa, and M. Baba. Novel reporter T-cell line highly susceptible to both CCR5- and CXCR4-using human immunodeficiency virus type 1 and its application to drug susceptibility tests. J. Clin. Microbiol. 2003, 41, 2515-2521.

74 Spenlehauer, C., C. A. Gordon, A. Trkola, and J. P. Moore. A luciferase-reporter gene-expressing T-cell line facilitates neutralization and drug-sensitivity assays that use either R5 or X4 strains of human immunodeficiency virus type 1 Virology 2001, 280, 292-300.

75 Wei, X., J. M. Decker, H. Liu, Z. Zhang, R. B. Arani, J. M. Kilby,

M. S. Saag, X. Wu, G. M. Shaw, and J. C. Kappes. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 2002, 46, 1896-1905.

76 Xiao, H., C. Neuveut, H. L. Tiffany, M. Benkirane, E. A. Rich,

P. M. Murphy, and K. T. Jeang. Selective CXCR4 antagonism by Tat: implications for in vivo expansion of coreceptor use by HIV-1. Proc. Natl. Acad. Sci. USA 2000, 97, 11466-11471.

77 Berger, E. A., R. W. Doms, E. M. Fenyo, B. T. Korber, D. R. Littman,

J. P. Moore, Q. J. Sattentau, H. Schuitemaker, J. Sodroski, and R. A. Weiss. A new classification for HIV-1. Nature 1998, 391, 240.

78 Bleul, C. C., L. Wu, J. A. Hoxie, T. A. Springer, and C. R. Mackay.

The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc. Natl. Acad. Sci. USA 1997, 94, 1925-1930.

79 Chesebro, B., and K. Wehrly. Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity. J. Virol. 1988, 62, 3779-3788.

80 Anand, R., F. Siegal, C. Reed, T. Cheung, S. Forlenza, and J. Moore. Non-cytocidal natural variants of human immunodeficiency virus isolated from AIDS patients with neurological disorders. Lancet 1987, 2, 234-238.

81 Larder, B. A., B. Chesebro, and D. D. Richman. Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay. Antimicrob. Agents Chemother. 1990, 34, 436-441.

82 Hsu, M. C., U. Dhingra, J. V. Earley, M. Holly, D. Keith, C. M. Nalin,

A. R. Richou, A. D. Schutt, S. Y. Tam, M. J. Potash, et al. Inhibition of type 1 human immunodeficiency virus replication by a tat antagonist to which the virus remains sensitive after prolonged exposure in vitro. Proc. Natl. Acad. Sci. USA 1993, 90, 6395-6399.

83 Nussbaum, O., C. C. Broder, and E. A. Berger. Fusogenic mechanisms of enveloped-virus glycoproteins analyzed by a novel recombinant vaccinia virus-based assay quantitating cell fusion-dependent reporter gene activation. J. Virol. 1994, 68, 5411-5422.

84 Wyatt, J. R., T. A. Vickers, J. L. Roberson, R. W. Buckheit, Jr., T. Klimkait, E. DeBaets, P. W. Davis, B. Rayner, J. L. Imbach, and D. J. Ecker. Combinatorially selected guanosine-quartet structure is a potent inhibitor of human immunodeficiency virus envelope-mediated cell fusion.

85 Hamy, F., E. R. Felder, G. Heizmann, J. Lazdins, F. Aboul-ela, G. Varani, J. Karn, and T. Klimkait. An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication. Proc. Natl. Acad. Sci. USA 1997, 94, 3548-3553.

86 Horscroft, N., V. C. Lai, W. Cheney, N. Yao, J. Z. Wu, Z. Hong, and W. Zhong. Replicon cell culture system as a valuable tool in antiviral drug discovery against hepatitis C virus. Antivir. Chem. Chemother. 2005, 16, 1-12.

87 Yi, M., F. Bodola, and S. M. Lemon. Subgenomic hepatitis C virus replicons inducing expression of a secreted enzymatic reporter protein. Virology 2002, 304, 197-210.

88 Lindenbach, B. D., P. Meuleman, A. Ploss, T. Vanwolleghem,

A. J. Syder, J. A. McKeating, R. E. Lanford, S. M. Feinstone, M. E. Major, G. Leroux-Roels, and C. M. Rice. Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc. Natl. Acad. Sci. USA 2006, 103, 3805-3809.

0 0

Post a comment